Home Cart Sign in  
Chemical Structure| 262352-17-0 Chemical Structure| 262352-17-0

Structure of Torcetrapib
CAS No.: 262352-17-0

Chemical Structure| 262352-17-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Torcetrapib is a CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma.

Synonyms: CP-529414; (–)-Torcetrapib

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Torcetrapib

CAS No. :262352-17-0
Formula : C26H25F9N2O4
M.W : 600.47
SMILES Code : O=C(N1[C@H](CC)C[C@H](N(CC2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)C(OC)=O)C3=C1C=CC(C(F)(F)F)=C3)OCC
Synonyms :
CP-529414; (–)-Torcetrapib
MDL No. :MFCD08063631

Safety of Torcetrapib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P264-P270-P301+P312-P330-P501

Isoform Comparison

Biological Activity

Target
  • CETP

    CETP, IC50:37 nM

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00136981 Hypercholesterolemia, Familial... More >> Hyperlipidemia Less << Phase 3 Completed - -
NCT00134173 Coronary Disease ... More >> Coronary Arteriosclerosis Hyperlipidemia Less << Phase 3 Completed - -
NCT00134238 Mixed Hyperlipidemia Phase 3 Terminated - -
NCT00137462 Hyperlipidemia Phase 3 Completed - -
NCT00452842 - Terminated(See termination rea... More >>son in detailed description.) Less << - United States, Florida ... More >> Pfizer Investigational Site Clearwater, Florida, United States, 33756 Less <<
NCT00138762 Hyperlipidemia Phase 3 Completed - -
NCT00267280 Hyperlipidemia ... More >> Dyslipidemia Hypercholesterolemia Less << Phase 3 Terminated - -
NCT00267254 Hyperlipidemia ... More >> Dyslipidemia Hypercholesterolemia Less << Phase 3 Completed - -
NCT00134498 Hypertriglyceridemia ... More >> Hyperlipoproteinemia Type IV Less << Phase 3 Completed - -
NCT00134485 Hypercholesterolemia, Familial... More >> Hyperlipidemia Less << Phase 3 Completed - -
NCT00145431 Hyperlipoproteinemia Type III Phase 3 Terminated - -
NCT00267267 Hyperlipidemia ... More >> Dyslipidemia Less << Phase 3 Terminated - -
NCT00134511 Hypercholesterolemia, Familial Phase 3 Completed - United States, Massachusetts ... More >> Pfizer Investigational Site Boston, Massachusetts, United States, 02114 Canada, Quebec Pfizer Investigational Site Chicoutimi, Quebec, Canada, G7H 5H6 Pfizer Investigational Site Ste-Foy, Quebec, Canada, G1V 4M6 South Africa Pfizer Investigational Site Parktown, Johannesburg, South Africa, 2193 Pfizer Investigational Site Bloemfontein, South Africa, 9301 Pfizer Investigational Site Cape Town, South Africa, 7925 Less <<
NCT00139061 Hyperlipidemia Phase 3 Completed - France ... More >> Pfizer Investigational Site Angers, France, 49 000 Pfizer Investigational Site Angers, France, 49 100 Pfizer Investigational Site Bordeaux Cauderan, France, 33 200 Pfizer Investigational Site Briollay, France, 49125 Pfizer Investigational Site Dijon, France, 21000 Pfizer Investigational Site Hagondange, France, 57 300 Pfizer Investigational Site Haut Mauco, France, 40 280 Pfizer Investigational Site Jarny, France, 54800 Pfizer Investigational Site Lille, France, 59 037 Cedex Pfizer Investigational Site Mars LA Tour, France, 54800 Pfizer Investigational Site Metz, France, 57070 Pfizer Investigational Site Monguilhem, France, 32 240 Pfizer Investigational Site Mont de Marsan CEDEX, France, 40010 Pfizer Investigational Site Mont de Marsan, France, 40 010 cedex Pfizer Investigational Site Mont de Marsan, France, 40 010 Pfizer Investigational Site Mont de Marsan, France, 40000 Pfizer Investigational Site Moutiers, France, 54660 Pfizer Investigational Site Murs Erigne, France, 49610 Pfizer Investigational Site Nantes, France, 44 093 Cedex 01 Pfizer Investigational Site Pouilly en Auxois, France, 21 850 Pfizer Investigational Site Saint Justin, France, 40 240 Pfizer Investigational Site Saint Martin D'Oney, France, 40090 Pfizer Investigational Site Seysses, France, 31600 Pfizer Investigational Site Strasbourg, France, 67000 Pfizer Investigational Site Thouars, France, 79100 Pfizer Investigational Site Tierce, France, 49 125 Less <<
NCT00134264 Coronary Disease ... More >> Diabetes Mellitus Less << Phase 3 Terminated - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.67mL

0.33mL

0.17mL

8.33mL

1.67mL

0.83mL

16.65mL

3.33mL

1.67mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories